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Table 1. Organizational Schema of Consortium
Clinical Sites/PIs External DSMC Scientific Advisory Committee Cores
NYMC:Mitchell S. Cairo, MD Michael Nieder, MD All Children’s
Hospital
Guido Lucarelli, MD University
of Tor Vergata
Donor Chimerism: LeeAnn
Baxter-Lowe, PhD (UCSF)
CHRCO:Mark Walters, MD Russell E. Ware, MD, PhD Baylor
College of Medicine
Adrian P. Gee, PhD Baylor
College of Medicine
Health Related Quality of Life: Susan
Parsons, MD (Tufts)
MCW: Julie-An Talano, MD Rupert Handgretinger, MD
Eberhard Karls Universit€at
T€ubingen
George Buchanan, MD
UT Southwestern
Neurocognition: Elizabeth Kera, PhD
(NYMC)
CUMC: Monica Bhatia, MD Daniel Heitjan, PhD UPenn Neuroimaging: Robert McKinstry, MD, PhD
(WashU)
Wash U: Shalini Shenoy, MD Pulmonary Function: Allen Dozor, MD
(NYMC)
Cell Processing Core Pulmonary Vascular Core: Deborah
Friedman, MD (NYMC) Rajamma
Mathew, MBBS (NYMC)
MCW: Carolyn Keever-Taylor, PhD;
WashU: Brenda Grossman, MD;
CUMC: Joseph Schwartz,MD;
Progenitor Cell Therapy:
Robert Preti, PhD
Immunology: NYMC: Mitchell S. Cairo, MD;
MCW: James Verbsky, MD, PhD, Jack
Gorski, PhD, and Carolyn Keever-Taylor, PhD
Radiation Therapy: R. Chitti, MD (NYMC)
Poster Session I S303Methods: Patients 2-20.99 years of age and who meet SCURT eli-
gibility without an 8/8 HLA matched unrelated donor will be en-
rolled. Patients will receive hydroxyurea (60mg/kg/day) and
azathioprine (3mg/kg/day) from days-59 to -11. Fludarabine
(30mg/m2) will be given for 6 days (day -17 to -13), busulfan
(4mg/kg/day) for 4 days (day -12 to -9) and cyclophosphamide for
4 days (day -7 to -4), thiotepa (10mg/kg, day -8), R-ATG (day -5
to -2), TLI (500cGy) followed by FHI T-cell depleted AlloSCT.
GVHD prophylaxis will consist of tacrolimus. HPC, Apheresis-
CD34-enriched cells will be collected by the CliniMACS (FDA
IND14359) with a target dose of 10.0 x 106 CD34+ cells/kg contain-
ing 2.0 x 105 CD3+ T cells/kg.
Results:Wehave developed a FHITCDConsortium of five clinical
sites, four processing centers, and cores in donor chimerism,
anti-HLA antibodies, immunology, cell processing, biostatistics,
neuroimaging, neurocognition, quality of life, pulmonary function,
pulmonary vascular, radiation, and a patient advocacy group
(www.haploscdconsortium.org) (Table 1).
Conclusion:We seek to develop a unique opportunity for high-risk
SCD patients to be cured of this debilitating disease, potentially im-
proving organ function, quality of life, and neurocognition while
providing a universal allogeneic donor source for many more at-
risk SCD patients.266
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Background: EBV-PTLD is a life threatening complication after
allo-HSCT. No risk factor analysis for outcome of PTLD therapy
has been reported so far. OBJECTIVE: Analysis of the risk factors
influencing the outcome of rituximab-based treatment of EBV-
PTLD after allo-HSCT in children.
Patients and Methods: PTLD was diagnosed in 55 (2.7%) cases of
the 2050 children given an allo-HSCT; biopsy-proven in 28 (50.5%)
cases or probable disease (lymphadenopathy with serumEBV-DNA-
emia) in the remainder. The median age at transplant was 7.8 years
(range, 0.3-16.8). Seven cases developed in HLA-identical siblings
(MFD), 7 in mismatched family/haplo, 23 in MUD and 18 in
MMUD. The source of stem cells: 32 PB, 18 BM and 5 CB. Patients
were treated weekly with a median of 3 doses of rituximab (range,
1-16) and with median of 375 mg/m2 per dose. Early response and
failure after therapy were defined by 1-log decrease and 1-log in-
crease, respectively, of EBV-DNA load at 1 week after the first
dose of rituximab.
Results:The incidence of EBV-PTLD ranged from 0.9% inMFD-
HSCT, 1.6% in MMFD/haplo-HSCT, 3.5% in MUD-HSCT, to
7.6% inMMUD-HSCT, and 3.1% in CBT) and developed in a me-
dian of 2 months (range, 0.2-81) after allo-HSCT. Resolution of
PTLD after rituximab therapy was observed in 43 (78%) cases.
The initial risk factors influencing outcome of PTLD therapy
were: EBV serology positive donor and recipient (HR 5 5, p 5
0.032), involvement of extra-lymphoid tissue (HR 5 9, p 5 0.037),
initial plasma EBV-DNA load .10^5 gc/mL (HR 5 8.3, p 5
0.002) but after multivariate analysis only involvement of extra-lym-
phoid tissue (HR5 9, p5 0.041) and initial plasma EBV-DNA load
.10^5 gc/mL (HR 5 7.7, p 5 0.003) remained significant. The re-
sponse to therapy, determined by .1 log decrease of EBV-DNA
load after 1 week of therapy (HR 5 0.17, p 5 0.015) and reduction
of immunosuppression contributed to better outcome (HR 5 0.23,
p 5 0.059) whereas an increase of EBV-DNA load during therapy
by .1 log (HR 5 8, p 5 0.004) corresponded to a worse outcome.
Reduction of immunosuppression possibly contributed to better sur-
vival from PTLD (HR 5 0.23, p 5 0.059).
Conclusions: Overall 78% of children with EBV-PTLD after allo-
HSCT responded to treatment with rituximab and early response
after 1 week of therapy correspondedwith a good prognosis. Involve-
ment of extra-lymphoid tissue, initial plasmaEBV-DNA load.10^5
gc/mL and increase of EBV-DNA load during therapy by 1 log were
predictors of poor outcome.
